Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics Inc (BJDX) is a pioneer in rapid sepsis detection through its innovative Symphony™ platform, delivering critical IL-6 biomarker results in emergency care settings. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical validations, and strategic partnerships.
Access authoritative information about BJDX's progress in transforming critical care diagnostics, including earnings reports, product development timelines, and peer-reviewed study outcomes. Our curated news collection simplifies tracking of FDA clearances, technology enhancements, and market expansion initiatives relevant to near-patient testing solutions.
Key updates include developments in sepsis triage protocols, Symphony platform deployments, and clinical utility studies demonstrating IL-6's prognostic value. Bookmark this page for real-time notifications about BJDX's advancements in cost-effective rapid diagnostics that support time-sensitive treatment decisions.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported its financial results for 2022, highlighting key developments in its Symphony platform, aimed at improving patient outcomes in critical care. The company received positive FDA feedback on expanding its clinical study, pushing the anticipated de novo submission to the first half of 2024. As of December 31, 2022, cash and equivalents decreased to $10.1 million from $19.0 million in 2021. Research and development expenses surged by 262% to $3.0 million, while general and administrative costs increased by 166%. The net loss for the year was $9.3 million, or $0.46 per share, compared to $3.5 million, or $0.41 per share in 2021.
Bluejay Diagnostics (NASDAQ: BJDX) has entered a collaborative agreement with Blood Centers of America (BCA) to address unmet needs in the blood and hospital markets using its Symphony Platform. This partnership allows Bluejay to access BCA's extensive network of over 60 blood centers, potentially enhancing the delivery of critical care solutions. The collaboration aims to support clinical studies and explore Symphony's applications in the blood supply industry. Bluejay's Symphony IL-6 Test, designed for rapid sepsis triage, will play a pivotal role in this initiative, addressing urgent patient care needs.
FAQ
What is the current stock price of Bluejay Diagnostics (BJDX)?
What is the market cap of Bluejay Diagnostics (BJDX)?
